Efeitos do Casirivimabe e Imdevimabe no tratamento do COVID-19: uma revisão integrativa

Authors

  • Paulo Vytor Cardoso Nobre
  • Guilherme Augusto Grangeiro Amorim
  • Abrahao Verçosa Amorim Filho
  • Laís Acioli Lins
  • João Victor Nunes Cadete
  • Ray de Lima Coutinho Costa
  • Maria Luísa Vieira Cuyabano Leite
  • Josivaldo de Araújo Alves Júnior
  • Caio Cesar Gusmão Costa Coutinho
  • Luis Guilherme Gomes de Athayde
  • Henrique José Fernandes de Souza Vieira
  • Hérica Silva Florentino
  • Túlio Lustosa de Oliveira Avelino Lopes

DOI:

https://doi.org/10.55905/revconv.17n.6-089

Keywords:

casirivimabe-imdevimabe, anticorpo monoclonal, COVID-19, tratamento

Abstract

Introdução: A terapia de anticorpos monoclonais Casirivimabe-imdevimabe é uma importante ferramenta no manejo do COVID-19, projetada para se ligar à proteína spike do coronavírus SARS-CoV-2, buscando impedir a entrada do vírus nas células humanas.  Objetivo: avaliar os impactos do casirivimabe-imdevimabe no tratamento da COVID-19. Métodos: Consiste em uma revisão integrativa realizada através das bases BVS, PubMed® e SciELO, utilizando os descritores casirivimabe-imdevimabe, COVID-19 e tratamento. Foram incluídos estudos publicados nos últimos 4 anos, em idioma inglês, espanhol ou português, que abordassem a temática. Resultados e discussões: Evidenciou-se que o uso de casirivimabe-imdevimabe está relacionado à uma menor taxa de mortalidade em comparação com o grupo controle não submetido ao tratamento, além de reduzir significativamente as internações hospitalares. Conclusão: O tratamento com casirivimabe-imdevimabe reduz as taxas de mortalidade em pacientes com COVID-19, mostrando potencial na gestão da doença. Contudo, mais estudos são necessários para validar esses resultados em diversas populações, variantes e estágios da doença.

References

AL-OBAIDI, M. M. et al. Effectiveness of casirivimab-imdevimab monoclonal antibody treatment among high-risk patients with severe acute respiratory syndrome coronavirus 2 B.1.617.2 (Delta variant) infection. Open Forum Infect Dis, v. 9, 2022. DOI: 10.1093/ofid/ofac186.

BAUM, A. et al. Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies. Science, v. 369, p. 1014–1018, 2020.

BIERLE, D. M. et al. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. J Clin Virol, v. 145, 2021. DOI: 10.1016/j.jcv.2021.105026.

HANSEN, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science, v. 369, p. 1010–1014, 2020.

JOY, A. P. et al. The impact of casirivimab-imdevimab antibody cocktail in patients amidst and post COVID 19 treatment: a retro-prospective comparative study in India. J Assoc Physicians India, v. 70, p. 11–12, 2022.

MCCREARY, E. K. et al. Association of subcutaneous or intravenous administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in adults with COVID-19. JAMA Netw Open, v. 5, 2022. DOI: 10.1001/jamanetworkopen.2022.6920.

O'BRIEN, M. P. et al. Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: a randomized clinical trial. JAMA, v. 327, 2022. DOI: 10.1001/jama.2021.24939.

PORTAL-CELHAY, C. et al. Virologic efficacy of casirivimab and imdevimab COVID-19 antibody combination in outpatients with SARS-CoV-2 infection: a phase 2 dose-ranging randomized clinical trial. JAMA Netw. Open, 2022. DOI: 10.1001/jamanetworkopen.2022.25411.

RAZONABLE, R. R. et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. eClinicalMedicine, v. 40, 2021. DOI: 10.1016/j.eclinm.2021.101102.

RHUDY, C. et al. Impact of a subcutaneous casirivimab and imdevimab clinic in outpatients with symptomatic COVID-19: a single-center, propensity-matched cohort study. Am J Health Syst Pharm, v. 80, p. 130–136, 2023. DOI: 10.1093/ajhp/zxac305.

SHI, R. et al. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. Nature, v. 584, p. 120–124, 2020.

SOMERSAN-KARAKAYA, S. et al. Casirivimab and imdevimab for the treatment of hospitalized patients with COVID-19. J. Infect. Dis, v. 227, p. 23–34, 2022. DOI: 10.1093/infdis/jiac320.

SUZUKI, Y. et al. Real-world clinical outcomes of treatment with casirivimab-imdevimab among patients with mild-to-moderate coronavirus disease 2019 during the Delta variant pandemic. Int J Med Sci, v. 19, p. 834–841, 2022. DOI: 10.7150/ijms.71132.

WALLS, A. C. et al. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell, v. 181, p. 281–292, 2020.

WANG, C. et al. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun, v. 11, 2020.

WEINREICH, D. M. et al. REGEN-COV antibody combination and outcomes in outpatients with covid-19. N. Engl. J. Med, v. 385, 2021. DOI: 10.1056/nejmoa2108163.

WEINREICH, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N. Engl. J. Med, v. 384, 2021. DOI: 10.1056/nejmoa2035002.

WINKLER, E. S. et al. Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection. Cell, v. 184, p. 1804–1820, 2021.

Published

2024-06-10

How to Cite

Nobre, P. V. C., Amorim, G. A. G., Amorim Filho, A. V., Lins, L. A., Cadete, J. V. N., Costa, R. de L. C., Leite, M. L. V. C., Alves Júnior, J. de A., Coutinho, C. C. G. C., Athayde, L. G. G. de, Vieira, H. J. F. de S., Florentino, H. S., & Lopes, T. L. de O. A. (2024). Efeitos do Casirivimabe e Imdevimabe no tratamento do COVID-19: uma revisão integrativa. CONTRIBUCIONES A LAS CIENCIAS SOCIALES, 17(6), e7369. https://doi.org/10.55905/revconv.17n.6-089

Issue

Section

Articles